United Therapeutics Corporation

NASDAQ:UTHR

Biotechnology

Healthcare
$577.34 -3.27%

-$18.01 today

Market cap
$24.59B
Beta
0.57
P/E (TTM)
18.0
EPS (TTM)
$29.60
52W Low $272.12High $609.35

Volume 0.42M

Average 0.52M

UTHR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

United Therapeutics CorporationNASDAQ: UTHR

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to 87.3%

Gross margin was 87.3% in Q2 FY2026, down 1.7 pp from a year earlier. On a trailing-twelve-month basis it was 86.1%, down 2.8 pp year over year. Over 3 fiscal years it narrowed by 4.5 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
87.3%+4.4 pp QoQ
Last fiscal yearDec 2025
87.9%-1.3 pp YoY
LTMJun 2026
86.1%-2.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.7 pp——
1 year-1.3 pp——
3 years-4.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
87.9%
Year-over-year change
-1.3pp

Gross Margin vs competitors

How UTHR compares with its peers on the latest reported figures

  • UTHR's LTM Jun 2026 gross margin of 86.1% is the 2nd highest of the 4 companies compared; the peer median is 83.3%.
  • Its year-over-year change of -2.8 pp is the 3rd highest of 4, against a peer median of +7.6 pp.
  • Over three fiscal years its change of -4.5 pp compares with a peer median of +1.9 pp.
UTHR Competitors Peer median
Gross Margin for UTHR and competitors
Company Period LTM level YoY 3-year change
LQDALiquidia CorporationLTM Jun 202692.5% +22.1 pp+9.6 pp
UTHRUnited Therapeutics CorporationLTM Jun 202686.1% -2.8 pp-4.5 pp
INSMInsmed IncorporatedLTM Jun 202683.3% +7.6 pp+1.9 pp
TVTXTravere Therapeutics, Inc.LTM Sep 202660.7% -37.0 pp+1.9 pp
IKTInhibikase Therapeutics, Inc.FY2025— ——
Peer median (excluding UTHR) 83.3%+7.6 pp+1.9 pp

Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.69B1.94B2.33B2.88B3.18B
Cost of Revenue122.5M146.7M257.5M309.7M384.4M
Gross Profit1.56B1.79B2.07B2.57B2.8B
Gross Margin92.7%92.4%88.9%89.2%87.9%
Research & Development540.1M322.9M408M481M550M
Selling, General & Admin467M487M477.1M638.6M731.1M
Operating Expenses1.01B809.9M885.1M1.19B1.28B
Depreciation & Amortization49.9M51.3M53.2M72.5M85.6M
EBITDA736.8M1.04B1.39B1.65B1.82B
EBITDA Margin43.7%53.7%59.6%57.5%57.2%
Operating Income555.9M979.7M1.18B1.38B1.52B
Operating Margin33.0%50.6%50.9%47.9%47.7%
Interest Income16.7M45.2M162.7M199.1M192M
Interest Expense18.6M32.4M59.3M42.9M19.5M
Other Income / Expenses38M(29.1M)89.4M162M196.7M
Income Before Tax593.9M950.6M1.27B1.54B1.71B
Pre-Tax Margin35.2%49.1%54.7%53.5%53.9%
Income Tax Expense118.1M223.3M289.5M343.9M379.2M
Net Income475.8M727.3M984.8M1.2B1.33B
Net Margin28.2%37.6%42.3%41.5%41.9%
EPS (Basic)10.6015.9821.0426.4430.13
EPS (Diluted)10.0615.0019.8124.6427.86
Weighted Avg Shares44.9M45.5M46.8M45.2M44.3M
Weighted Avg Shares (Diluted)47.3M48.5M49.7M48.5M47.9M

United Therapeutics Corporation

NASDAQ:UTHR

Intrinsic Alpha fair value

Locked

Current Price

$577.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.